Catalyst
Slingshot members are tracking this event:
Summit Enrolls Patients in the United States Into PhaseOut DMD, a Phase 2 Clinical Trial of Ezutromid in Patients With DMD
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| SMMT |
|
|
||||
Slingshot Insights Explained
Catalyst Date
Occurred on:
Nov 16, 2016
Related Projects
Related Keywords
Ezutromid, Dmd, Phaseout Dmd, Phase 2, Utrophin Modulator
